Tufton Capital Management Sells 375 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Tufton Capital Management lessened its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 27.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 993 shares of the medical equipment provider’s stock after selling 375 shares during the period. Tufton Capital Management’s holdings in Intuitive Surgical were worth $335,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ISRG. Norges Bank purchased a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $915,360,000. WCM Investment Management LLC purchased a new stake in shares of Intuitive Surgical in the fourth quarter valued at approximately $575,536,000. Morgan Stanley boosted its holdings in shares of Intuitive Surgical by 29.9% in the fourth quarter. Morgan Stanley now owns 5,866,613 shares of the medical equipment provider’s stock valued at $1,556,706,000 after purchasing an additional 1,351,002 shares during the period. Barclays PLC boosted its holdings in shares of Intuitive Surgical by 159.5% in the second quarter. Barclays PLC now owns 1,379,246 shares of the medical equipment provider’s stock valued at $471,619,000 after purchasing an additional 847,651 shares during the period. Finally, International Assets Investment Management LLC boosted its holdings in shares of Intuitive Surgical by 32,360.5% in the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after purchasing an additional 684,749 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Truist Financial upped their price target on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Barclays upped their price target on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research report on Thursday, January 25th. Wells Fargo & Company upped their price target on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research report on Friday, January 19th. Raymond James upped their price target on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Finally, StockNews.com downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average target price of $375.70.

Intuitive Surgical Price Performance

Intuitive Surgical stock traded down $0.71 during midday trading on Thursday, reaching $373.46. The company had a trading volume of 663,362 shares, compared to its average volume of 1,621,944. The company has a market capitalization of $132.37 billion, a P/E ratio of 74.39, a P/E/G ratio of 5.88 and a beta of 1.36. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76. The firm’s fifty day simple moving average is $387.56 and its 200-day simple moving average is $342.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.48 by $0.12. The firm had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.89 billion. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. Intuitive Surgical’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period last year, the company posted $0.91 EPS. On average, analysts expect that Intuitive Surgical, Inc. will post 4.93 EPS for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Mark Brosius sold 196 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares of the company’s stock, valued at approximately $736,800. The disclosure for this sale can be found here. In the last quarter, insiders sold 248,418 shares of company stock worth $95,927,097. Insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.